tiprankstipranks
Trending News
More News >

Guangzhou Baiyunshan to Review Q1 2025 Financial Results

Story Highlights
  • Guangzhou Baiyunshan operates in the pharmaceutical industry, focusing on medicinal products.
  • The board will meet to approve Q1 2025 financial results, impacting stakeholder insights.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Guangzhou Baiyunshan to Review Q1 2025 Financial Results

Confident Investing Starts Here:

Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has provided an announcement.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced that its board of directors will meet on April 29, 2025, to review and approve the unaudited financial results for the first quarter of 2025. This meeting is significant as it provides insights into the company’s financial health and operational performance, which are crucial for stakeholders and investors monitoring the company’s market position and future prospects.

More about Guangzhou Baiyunshan Pharmaceutical Holdings Company

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company is based in Guangzhou, China, and is involved in the development and sale of various medicinal products and health-related services.

YTD Price Performance: 3.49%

Average Trading Volume: 30,548

Technical Sentiment Signal: Buy

Current Market Cap: $5.48B

Learn more about 0874 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1